Abstract

Esophageal cancer (EC) is the seventh most common cancer worldwide and the sixth leading cause of death, according to Globocan 2018. Despite efforts made for therapeutic advances, EC remains highly lethal, portending a five-year overall survival of just 15–20%. Hence, the discovery of new molecular targets that might improve therapeutic efficacy is urgently needed. Due to high proliferative rates and also the limited oxygen and nutrient diffusion in tumors, the development of hypoxic regions and consequent activation of hypoxia-inducible factors (HIFs) are a common characteristic of solid tumors, including EC. Accordingly, HIF-1α, involved in cell cycle deregulation, apoptosis, angiogenesis induction and proliferation in cancer, constitutes a predictive marker of resistance to radiotherapy (RT). Deregulation of epigenetic mechanisms, including aberrant DNA methylation and histone modifications, have emerged as critical factors in cancer development and progression. Recently, interactions between epigenetic enzymes and HIF-1α transcription factors have been reported. Thus, further insight into hypoxia-induced epigenetic alterations in EC may allow the identification of novel therapeutic targets and predictive biomarkers, impacting on patient survival and quality of life.

Highlights

  • Esophageal cancer (EC) incidence has increased in recent decades, representing the seventh most common cancer worldwide and the sixth cause of cancer-related death, according to Globocan2018 [1], with an overall five-year survival ranging from 15–20% [2,3]

  • Kim et al have was associated with hypoxia-inducible factors (HIFs)-1α signaling pathways, being significantly overexpressed in the Lewis lung demonstrated the critical role of histone deacetylases (HDAC)-induced hypoxia in angiogenesis and tumor progression carcinoma model, increasing angiogenesis [67]

  • Research in Oncology has been focused on the identification of key targetable molecules among the most relevant signaling pathways, which might allow for the implementation of Precision Medicine

Read more

Summary

Introduction

Esophageal cancer (EC) incidence has increased in recent decades, representing the seventh most common cancer worldwide and the sixth cause of cancer-related death, according to Globocan. Most ECs are diagnosed at advanced stages, in which primary surgery is not an effective therapy [9], entailing the need for multimodal treatments. In this setting, neoadjuvant chemoradiotherapy (CRT) achieves the highest complete pathological response rates, significantly improving EC patients’ overall outcomes [8,9,10]. RT causes a redox imbalance in favor of excessive oxidation [14], and must overcome the redox defenses of tumor cells in order to be effective In this context, hypoxia is highly detrimental as it interferes with the fixation of DNA damage causing resistance to RT.

Biological Basis of Cancer Radiation Therapy
Cancer Epigenetics: A Brief Overview
Epigenetic
Epigenetic Remodeling and Hypoxic Microenvironment
Epigenetic Modifications and Radiosensitivity
Emerging
Findings
Conclusions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call